On February 7, 2022 Kyowa Kirin Co., Ltd. (hereinafter, the "Company") reported that it has recorded extraordinary income in the non-consolidated financial statements for Fiscal 2021 (January 1, 2021 to December 31, 2021) (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607778]). The details are as follows.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Details of extraordinary income The Company had provided an allowance for doubtful accounts for bonds issued by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., which is an associate accounted for using the equity method of the Company, that the Company had underwritten. However, given the fact that the bonds have started to be repaid and in consideration of the repayment schedule going forward, etc., the Company recorded extraordinary income of ¥29,834 million as reversal of allowance for doubtful accounts for subsidiaries and associates in the non-consolidated financial statements for the fiscal year ended December 31, 2021.

2. Impact on consolidated financial results Because the reversal of allowance for doubtful accounts for subsidiaries and associates was eliminated in the consolidated financial statements, there is no impact on the consolidated financial results.